Mind your fingers as the IPO window closes
29 June, 2004 by Renate KrelleMarket analysts are wondering whether the windown for Australian biotech IPOs has slammed shut.
UNSW spin-out Acyte collaborates with Serono
22 June, 2004 by Renate KrelleAcyte Biotechnology, a spin-out from the University of New South Wales, is to team up with Swiss biopharmaceutical giant Serono to develop recombinant proteins using Acyte's mammalian cell expression technology.
How Myriad's GCAT got out of the bag
21 June, 2004 by Graeme O'NeillThe past two decades have produced a plethora of patents for DNA diagnostic tests to determine people's susceptibility to common, life-threatening disorders like cancer, cardiovascular disease, hypertension and neurodegenerative diseases like Alzheimer's disease and motor neuron disease.
What not to do: the top 10 patenting mistakes
21 June, 2004 by Renate KrelleYou've run your experiments, got your results, and you've been mentally spending -- or at least licensing -- the proceeds of your bulging IP portfolio. But that may have been the easy part, writes Renate Krelle. Before you go any further, here's a checklist of some of the most common patenting pitfalls.
The end of the pioneer trail
21 June, 2004 by Melissa TrudingerAustralia's first ever Cooperative Research Centre is winding up operations. Melissa Trudinger joined its stakeholders for a look back at its successes.
COVER STORY: Lab to order
21 June, 2004 by Susan WilliamsonImagine if you could map out your dream lab on the concrete floor -- and then stock it with whatever you wanted. Susan Williamson spoke with Ian Findlay and his team at Gribbles Molecular Science, who did just that.
Interview: ViaLactia CEO Colin South
18 June, 2004 by Graeme O'NeillEven after its R&D budget was cut this week by parent company Fonterra, ViaLactia still has one of the biggest research budgets in New Zealand's biotechnology industry. CEO Colin South discussed his company's research programs with Australian Biotechnology News during a tour sponsored by New Zealand Trade and Enterprise in March.
Nanotech pioneer amongst new federation fellows
17 June, 2004 by Susan WilliamsonTwenty-five scientists will receive a $235,000 salary each year for the next five years, plus several hundred thousand dollars each in on-costs support, under the federation fellowships announced today by the federal government.
CRO Novotech springboards into US
15 June, 2004 by Melissa TrudingerAustralian CRO Novotech is setting up operations in the US to take advantage of the clinical trials opportunities offered there.
Watson to quit Genesis' helm
15 June, 2004 by Graeme O'NeillOne of the most familiar faces and names in New Zealand's biotechnology industry, Genesis Research & Development Corp CEO Dr Jim Watson, is retiring -- but only as far as the research bench.
Peptech and Agenix call off merger
09 June, 2004 by Renate KrelleSydney-based Peptech (ASX:PTD) and Brisbane-based Agenix (ASX:AGX) have called off their merger, citing Peptech's inability to provide Agenix with details of possible royalties due from Johnson & Johnson subsidiary Centocor.
BIO 2004: Call for closer Singapore-Australia biotech ties
09 June, 2004 by Melissa TrudingerThe Singapore and Australian biotechnology industries have synergies that should be exploited, the director of the Singapore Economic Development Board, Dr Swan-Gin Beh, has told a session at the BIO 2004 conference in San Francisco this week.
Sirtex to manufacture isotopes in US
08 June, 2004 by Graeme O'NeillSydney biomedical company Sirtex Medical Ltd (ASX:SRX) has announced it has purchased a US manufacturing site in Wilmington, Massachusetts, at a cost of US$990,000, funded though a mortgage over the property.
BIO 2004: Vics restate biotech dominance aim
07 June, 2004 by Melissa TrudingerVictorian premier Steve Bracks has used the BIO 2004 conference, which kicked off in San Francisco on Sunday, as a platform to reiterate the state's ambitious plan to become one of the top five biotechnology locations globally by 2010.
Tropical science: Survival of the fittest
02 June, 2004 by Susan WilliamsonHer 30-year career has taken her from Sydney to Wales to South Africa, from biology at Wollongong to nuclear science at Australia's only research reactor. And now Prof Helen Garnett has a new challenge, as vice-chancellor of the Northern Territory's new Charles Darwin University.
